Lipid nanoparticles (LNPs) are one of the most significant advances in drug delivery in decades. But developing successful LNP formulations demands deep knowledge of their key building blocks: Lipids.
In the wake of several high-profile eye drop recalls, we look at the challenges of achieving sterility in ophthalmic products, the consequences of failing to do so, and how AbbVie Contract Manufacturing ensures product sterility and safety.
Global Vice President of Analytical & Research Development, Scott Zugel, spoke at Veranova’s SCALE Symposium, where he outlined key analytical strategies and challenges in ADC manufacturing in the pharmaceutical industry.
Controlled release technologies are helping small molecule therapeutics deliver more consistent drug exposure, improve patient adherence, reduce dosing frequency, and support more precise treatment through advanced formulation and delivery strategies.
Allogeneic CAR T therapies are helping move oncology toward more scalable, off-the-shelf treatment models that could expand access, support earlier intervention, and bring advanced cell therapy closer to community cancer settings.
Self-administered drug-device combination products can bring major benefits to clinical trials, improving patient convenience, dosing consistency, compliance, and real-world insight, but they require careful early planning around usability, safety, regulatory requirements, compatibility, manufacturing, and scale-up.
Masha Kononov and Reuben Carr examine both the promise and the practical constraints of biocatalysis in modern drug substance development, as well as the role of contract research, development and manufacturing organizations (CRD-MOs) in meeting the evolving demands of modern small molecule synthesis.
Pace® Life Sciences provides a full suite of contract CMC development, CTM manufacturing, regulatory compliance, consulting, and facility support services to the pharmaceutical, biopharmaceutical, and gene therapy industries. We operate from a network of CDMO sites, GMP analytical testing laboratories, and manufacturing support service centers across the United States.
Our highly trained industry experts, and investment in state-of-the-art facilities emphasize our commitment to efficiently advancing client programs through the clinic to commercialization. We are dedicated to delivering the most reliable services with positive customer experiences across all channels of our business.
Late-stage surprises continue to drive cost, delay, and challenges in oral solid dosage (OSD) development—especially for complex, poorly soluble molecules. Too often, formulation and manufacturability risks surface only after significant time and investment.
In a recent panel discussion, GlobalData’s Director …
Bioabsorbable poly(lactide-co‑glycolide) (PLG) polymers and poly(lactic acid-co-glycolic acid) (PLGA) have become an essential part of modern healthcare. Over the past five decades, these polymers have transformed how medicines are delivered – enabling long-acting injectables, implants, and localized drug‑delivery products …
As drug development grows more complex and timelines compress, sponsors require CDMO relationships built on integration, flexibility, and shared accountability. The relationship between pharmaceutical sponsors and their CDMO partners has undergone a fundamental …
Why Early Development Requires a Different Decision Model
Early oral drug development is an exercise in working under constraint. Teams are asked to make consequential decisions when materials are limited, timelines are tight, and the data are incomplete. Traditionally, formulation …
The white paper, Small Molecules: Choosing the Right Development Path, outlines a structured, risk-minimized approach to early CMC (Chemistry, Manufacturing, and Controls) development for small-molecule drugs—particularly for startups and virtual pharma companies with limited resources.
Key messages:
Start
…
DRUG DEVELOPMENT DIRECT RESOURCES
Upcoming eNewsletter Features:
July 15 – ODT/Fast Dissolve
July 22 – Transdermal/Topical
July 29 – Drug Delivery
August 5 – Injection Devices